Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes
ABSTRACT Background Schlafen 11 (SLFN‐11) has been identified as a sensitizer of tumor cells to DNA‐damaging agents. However, the relationship between SLFN‐11 expression and clinical outcomes in patients with small cell lung cancer (SCLC) remains unexplored. Thus, we aimed to evaluate the impact of...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15529 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850030344396341248 |
|---|---|
| author | Ken Masuda Tatsuya Yoshida Noriko Motoi Yuki Shinno Yuji Matsumoto Yusuke Okuma Yasushi Goto Hidehito Horinouchi Noboru Yamamoto Shun‐ichi Watanabe Tomoaki Hoshino Yasushi Yatabe Yuichiro Ohe |
| author_facet | Ken Masuda Tatsuya Yoshida Noriko Motoi Yuki Shinno Yuji Matsumoto Yusuke Okuma Yasushi Goto Hidehito Horinouchi Noboru Yamamoto Shun‐ichi Watanabe Tomoaki Hoshino Yasushi Yatabe Yuichiro Ohe |
| author_sort | Ken Masuda |
| collection | DOAJ |
| description | ABSTRACT Background Schlafen 11 (SLFN‐11) has been identified as a sensitizer of tumor cells to DNA‐damaging agents. However, the relationship between SLFN‐11 expression and clinical outcomes in patients with small cell lung cancer (SCLC) remains unexplored. Thus, we aimed to evaluate the impact of SLFN‐11 expression on survival in patients with limited‐stage (LS) SCLC. Methods We conducted a retrospective review of data from patients pathologically diagnosed with LS‐SCLC post‐surgery between January 2008 and December 2018. SLFN‐11 expression was assessed using immunohistochemistry in tissue microarrays and scored using a histology (H)‐score (range: 0–300). Results Overall, 86 patients were included in the analysis with a median H‐score of 43 for SLFN‐11 expression. Among the patients, 44 had high SLFN‐11 expression (provisionally defined as H‐score ≥ 43). No significant differences in clinical profiles were observed between the two groups (high and low SLFN expression). The median survival durations were not reached (NR; 95% confidence interval [CI]: 65.1 months to NR) and 33.5 months (95% CI: 24.2 months to NR) for patients with high and low SLFN‐11 expression, respectively (hazard ratio [HR]: 0.40, 95% CI: 0.19–0.81; p = 0.012). Among patients who relapsed post‐surgery (n = 21), the median survival durations were 22.0 (95% CI: 7.6–44.9 months) and 8.1 (95% CI: 1.8–24.6 months) months in patients with high and low SLFN‐11 expression, respectively (HR: 0.22, 95% CI: 0.06–0.84; p = 0.026). Conclusions High SLFN‐11 expression is associated with relatively longer survival in patients with LS‐SCLC in both those undergoing surgery and those who have relapsed. |
| format | Article |
| id | doaj-art-93b9cddd30104294b9ad006bc425e3e7 |
| institution | DOAJ |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-93b9cddd30104294b9ad006bc425e3e72025-08-20T02:59:14ZengWileyThoracic Cancer1759-77061759-77142025-01-01161n/an/a10.1111/1759-7714.15529Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical OutcomesKen Masuda0Tatsuya Yoshida1Noriko Motoi2Yuki Shinno3Yuji Matsumoto4Yusuke Okuma5Yasushi Goto6Hidehito Horinouchi7Noboru Yamamoto8Shun‐ichi Watanabe9Tomoaki Hoshino10Yasushi Yatabe11Yuichiro Ohe12Department of Thoracic Oncology National Cancer Center Hospital Tokyo JapanDepartment of Thoracic Oncology National Cancer Center Hospital Tokyo JapanDepartment of Diagnostic Pathology National Cancer Center Hospital Tokyo JapanDepartment of Thoracic Oncology National Cancer Center Hospital Tokyo JapanDepartment of Thoracic Oncology National Cancer Center Hospital Tokyo JapanDepartment of Thoracic Oncology National Cancer Center Hospital Tokyo JapanDepartment of Thoracic Oncology National Cancer Center Hospital Tokyo JapanDepartment of Thoracic Oncology National Cancer Center Hospital Tokyo JapanDepartment of Thoracic Oncology National Cancer Center Hospital Tokyo JapanDepartment of Thoracic Surgery National Cancer Center Hospital Tokyo JapanDivision of Respirology, Neurology, and Rheumatology, Department of Medicine Kurume University School of Medicine Fukuoka JapanDepartment of Diagnostic Pathology National Cancer Center Hospital Tokyo JapanDepartment of Thoracic Oncology National Cancer Center Hospital Tokyo JapanABSTRACT Background Schlafen 11 (SLFN‐11) has been identified as a sensitizer of tumor cells to DNA‐damaging agents. However, the relationship between SLFN‐11 expression and clinical outcomes in patients with small cell lung cancer (SCLC) remains unexplored. Thus, we aimed to evaluate the impact of SLFN‐11 expression on survival in patients with limited‐stage (LS) SCLC. Methods We conducted a retrospective review of data from patients pathologically diagnosed with LS‐SCLC post‐surgery between January 2008 and December 2018. SLFN‐11 expression was assessed using immunohistochemistry in tissue microarrays and scored using a histology (H)‐score (range: 0–300). Results Overall, 86 patients were included in the analysis with a median H‐score of 43 for SLFN‐11 expression. Among the patients, 44 had high SLFN‐11 expression (provisionally defined as H‐score ≥ 43). No significant differences in clinical profiles were observed between the two groups (high and low SLFN expression). The median survival durations were not reached (NR; 95% confidence interval [CI]: 65.1 months to NR) and 33.5 months (95% CI: 24.2 months to NR) for patients with high and low SLFN‐11 expression, respectively (hazard ratio [HR]: 0.40, 95% CI: 0.19–0.81; p = 0.012). Among patients who relapsed post‐surgery (n = 21), the median survival durations were 22.0 (95% CI: 7.6–44.9 months) and 8.1 (95% CI: 1.8–24.6 months) months in patients with high and low SLFN‐11 expression, respectively (HR: 0.22, 95% CI: 0.06–0.84; p = 0.026). Conclusions High SLFN‐11 expression is associated with relatively longer survival in patients with LS‐SCLC in both those undergoing surgery and those who have relapsed.https://doi.org/10.1111/1759-7714.15529immunohistochemistrylung cancerSchlafen 11small cell lung cancer |
| spellingShingle | Ken Masuda Tatsuya Yoshida Noriko Motoi Yuki Shinno Yuji Matsumoto Yusuke Okuma Yasushi Goto Hidehito Horinouchi Noboru Yamamoto Shun‐ichi Watanabe Tomoaki Hoshino Yasushi Yatabe Yuichiro Ohe Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes Thoracic Cancer immunohistochemistry lung cancer Schlafen 11 small cell lung cancer |
| title | Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes |
| title_full | Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes |
| title_fullStr | Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes |
| title_full_unstemmed | Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes |
| title_short | Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes |
| title_sort | schlafen 11 expression in patients with small cell lung cancer and its association with clinical outcomes |
| topic | immunohistochemistry lung cancer Schlafen 11 small cell lung cancer |
| url | https://doi.org/10.1111/1759-7714.15529 |
| work_keys_str_mv | AT kenmasuda schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT tatsuyayoshida schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT norikomotoi schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT yukishinno schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT yujimatsumoto schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT yusukeokuma schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT yasushigoto schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT hidehitohorinouchi schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT noboruyamamoto schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT shunichiwatanabe schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT tomoakihoshino schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT yasushiyatabe schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes AT yuichiroohe schlafen11expressioninpatientswithsmallcelllungcanceranditsassociationwithclinicaloutcomes |